Completed
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy - CV027-006
Aggiornato:
7 maggio, 2025
|
ClinicalTrials.gov
Sintesi in un linguaggio semplice